Stage IV Breast Cancer AJCC v6 and v7 Clinical Trials

52 clinical trials for Stage IV Breast Cancer AJCC v6 and v7 across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — RECRUITING
• A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer — RECRUITING · PHASE1
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity — RECRUITING · PHASE3
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer — COMPLETED · PHASE3
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian — ACTIVE_NOT_RECRUITING · PHASE1
• Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy — ACTIVE_NOT_RECRUITING
• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer — TERMINATED · PHASE3
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease — TERMINATED · PHASE1
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer — COMPLETED · PHASE2
• Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord — ACTIVE_NOT_RECRUITING · PHASE2
• Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases — COMPLETED · PHASE2
• Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer — TERMINATED · PHASE1
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE1
• Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer — COMPLETED · PHASE1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer — TERMINATED · PHASE1
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer — COMPLETED · PHASE3
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer — COMPLETED · PHASE2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer — TERMINATED · PHASE1
• Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer — SUSPENDED · PHASE3
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE2
• Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer — COMPLETED · PHASE2
• Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer — COMPLETED · PHASE1
• Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer — COMPLETED · PHASE2
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer — COMPLETED · PHASE2
• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer — COMPLETED · PHASE2
• Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery — TERMINATED · PHASE2
• Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer — TERMINATED · PHASE1
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies — TERMINATED · PHASE1
• Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy — TERMINATED
• F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy — TERMINATED · NA
• Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients — COMPLETED · PHASE1
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer — COMPLETED · PHASE2
• Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer — COMPLETED · PHASE2
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive — COMPLETED · PHASE3
• Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only — COMPLETED · PHASE1
• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer — WITHDRAWN · PHASE2
• MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer — COMPLETED · PHASE1
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery — WITHDRAWN · PHASE1
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer — COMPLETED · PHASE1

Refine this search